MCM
BVS icon

Manchester Capital Management’s Bioventus BVS Stock Holding History

Manchester Capital Management’s Portfolio BVS Stock Details BVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-22
Closed – – 981
2022
Q1 		$0 Sell
22
-5
-19% -$67 ﹤0.01% 1032
2021
Q4 		$0 Buy
+27
New +$384 ﹤0.01% 1015

Other funds holding BVS

EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
JIC
Juniper Investment Company New York $378M AUM 95.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

Manchester Capital Management's BVS Position: Q2 2022 in Review

Manchester Capital Management sold out of Bioventus (BVS) in Q2 2022, closing a stake of 22 shares.

Manchester Capital Management first reported a position in BVS in Q4 2021 and held it in 2 quarters. The position peaked at $0 in Q1 2022. 98 funds tracked by Wall St. Rank hold BVS as of Q2 2022.

  • Manchester Capital Management reported no remaining Bioventus position as of Q2 2022 after selling out during the quarter.
  • Manchester Capital Management sold 22 Bioventus shares in Q2 2022.
  • Manchester Capital Management first reported a position in Bioventus in Q4 2021 and held it in 2 quarters.
  • Manchester Capital Management's Bioventus position peaked at $0 in Q1 2022.
  • 98 funds tracked by Wall St. Rank held Bioventus as of Q2 2022.

Based on Manchester Capital Management's 13F filing for Q2 2022, filed 10 Aug 2022.